Diabetes and Parkinson's reach new breakthroughs through Living Cell Technologies
Written by Alyssa Clark
Thriving in the Australian market since 2004, Living Cell Technologies has proved to not quite be fully understood yet in the American marketplace, and thus could make an outstanding investment opportunity for North American investors in 2014. Dedicating most of its work to unraveling the terrible pains of both Diabetes and Parkinson’s disease, this up-and-coming biotechnology company has yet to reach its peak— and your wallet is going to want to be there when it does.
Living Cell Technology currently has a market value of approximately $27 million, and is hard at work developing two of its new therapeutic drugs Diabecell and Ntcell (Diabecell treats Type 1 Diabetes and Ntcell is a regenerative therapy treatment for Parkinson’s disease, working to stimulate nerve regeneration and protects from cell death). With the markets for both of these drugs seeming to be exponential in the United States alone, this company has yet to fully put down roots in the states and capitalize on the highly-populated markets in our pharmaceutical industry. Not only in the U.S., but the global market for both of these illnesses is extremely large and is forcing customers to exceed normal limitations in order to obtain these much-anticipated drugs.
Last year, shares for Ntcell picked up drastically after it had been tried and approved to be inserted directly into the patient’s brain in an Auckland hospital. This trial was then approved by the Data Safety monitoring board and an additional three patients were given the procedure, with the Board’s full support. Ntcell has been steadily chugging along in the Auckland market, riding silently underneath the American pharma radar. The same is to be said for the equally as effective Diabecell which has been deemed safe and fit for reducing the amount of insulin a patient needs on a daily basis. This drug reduces the incidence of “unaware hypoglycemia”, without increasing HbA1c.
Both of Living Cell Technology’s drugs could solve this current demand for respective market cures, the question remains: why haven’t these drugs taken off in the U.S. yet?
The global Parkinson’s drug market alone is set to reach $34 billion by the year of 2016— which has opportunity written all over it for pharma giants like Novo Nordisk and Pfizer. Currently the world’s largest insulin producer, Novo has recently projected that the oral Diabetes drug market will be worth an estimated $18 billion by 2020. With the numbers and stakes to gain set this high, it’s no wonder why pharma giants are scrambling to climb over each other in an attempt to get their hands on this “easy” profit market as soon as possible. The bottom line of this insight: the successful development and distribution of an effective drug could and will provide substantial gains for shareholders and investors.
NeuTigers: edge AI in healthcare
What is edge AI?
Edge AI is essentially a combination of edge computing and artificial intelligence. Algorithms are processed locally - directly on a mobile device or server - rather than in the cloud. This reduces cost, computing power and energy requirements. There are also claims that edge AI is so fast it is possible to reach near real-time analytics.
Edge AI devices include smart speakers, smart phones, laptops, robots, self-driven cars, drones, and surveillance cameras that use video analytics.
Who is NeuTigers?
NeuTigers is a spin-off company from Princeton University, formed in 2018 to apply edge AI and machine learning to solve challenges in healthcare, energy, productivity, and security.
With offices in Princeton, NJ, the company is based at one of the top AI accelerator programs of FutureLabs in New York, and has also established a subsidiary in Nice, France.
How is NeuTigers applying edge AI to healthcare?
The NeuTigers AI Technology Stack uses deep neural networks that mimic how the human brain perceives and interprets the world. The company has developed the StarDeepTM Smart Health Platform for health monitoring and biomedical imaging, to improve the accuracy and speed of diagnosing diseases.
NeuTigers say the platform has the potential to monitor and screen for thousands of conditions, when used in combination with medical devices and smart sensors already deployed in healthcare settings.
Are there any real world examples?
In January NeuTigers launched CovidDeep, a tool that predicts COVID-19 with more than 90% accuracy, using physiological data from a wristband along with blood pressure and blood oxygen readings. It then analyses the data and gives a prediction within two minutes.
This week NeuTigers announced a new study to detect the early signs of complications with sickle cell anaemia. Conducted at a hospital in Paris, the research will begin by looking at changes to skin response, heart beat, sleep and temperature to predict an acute episode of sickle cell anaemia, and how this impacts on the patients’ disease conditions and quality of life.
The second phase of the project is to expand with prospective studies across different sites in EU, Africa and the US to explore the models' accuracy and clinical effectiveness.
Adel Laoui, CEO and founder of NeuTigers, says: “The best way to deal with a crisis is to avoid it happening in the first place. We are now entering a new era where medical early warning systems have become a reality.
“We are excited at the possibility of deploying a technology that can save lives of patients dealing with sickle cell anaemia. The potential of the StarDeep platform to dramatically improve patient outcomes while slashing some of the highest costs of healthcare makes it one of the most exciting developments in preventative personal medicine.”